Firefly Neuroscience's EEG Tech Enhances ADHD Diagnosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy AIFF?
Source: stocktwits
- Technological Innovation: Firefly Neuroscience's EEG/ERP technology can analyze resting and cognitive EEG brain scans to identify patterns that differentiate hyperactive-impulsive, inattentive, and combined forms of ADHD, providing doctors with more accurate diagnostic support.
- Market Reaction: Following the announcement that its AI-powered technology could help identify ADHD subtypes, Firefly's stock soared approximately 50% on Friday, reaching its highest level in nearly five months, reflecting strong investor confidence in the technology's potential.
- Performance Growth: Since acquiring Evoke Neuroscience in May 2025, Firefly has increased EEG/ERP brain scan volumes by 33 times, and on March 4, the stock price surged 126%, showcasing a significant achievement with its commercial footprint expanding over 20-fold.
- Future Outlook: Firefly's acceptance into the NVIDIA Connect program aims to leverage NVIDIA's tools and resources to develop a foundational model of the human brain, with CEO Greg Lipschitz stating that the growing brain scan data and NVIDIA GPU acceleration will lead to further breakthroughs in cognitive brain biomarker discovery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AIFF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AIFF
About AIFF
Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company developing neuroscientific solutions to improve brain health outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics software platform (the BNA Platform) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. The Company's Brain Network Analytics is a neurophysiological assessment tool that uses artificial intelligence and machine learning to analyze electroencephalogram (EEG) data recorded during rest and cognitive activity. The BNA Platform, in conjunction with an EEG system, provides clinicians with comprehensive insights into brain function (cognition).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Firefly Neuroscience's EEG Tech Enhances ADHD Diagnosis
- Technological Innovation: Firefly Neuroscience's EEG/ERP technology can analyze resting and cognitive EEG brain scans to identify patterns that differentiate hyperactive-impulsive, inattentive, and combined forms of ADHD, providing doctors with more accurate diagnostic support.
- Market Reaction: Following the announcement that its AI-powered technology could help identify ADHD subtypes, Firefly's stock soared approximately 50% on Friday, reaching its highest level in nearly five months, reflecting strong investor confidence in the technology's potential.
- Performance Growth: Since acquiring Evoke Neuroscience in May 2025, Firefly has increased EEG/ERP brain scan volumes by 33 times, and on March 4, the stock price surged 126%, showcasing a significant achievement with its commercial footprint expanding over 20-fold.
- Future Outlook: Firefly's acceptance into the NVIDIA Connect program aims to leverage NVIDIA's tools and resources to develop a foundational model of the human brain, with CEO Greg Lipschitz stating that the growing brain scan data and NVIDIA GPU acceleration will lead to further breakthroughs in cognitive brain biomarker discovery.
See More
Firefly Neuroscience Shares Surge 48% on ADHD Biomarker Discovery
- Breakthrough Discovery: Firefly Neuroscience announced a breakthrough in identifying new brain-wave biomarkers that may help distinguish between the three major subtypes of ADHD, leading to a stock price surge of over 48%.
- FDA-Cleared Platform: The findings stem from Firefly's FDA-cleared Evoke EEG/ERP platform, which employs AI to analyze brain signal patterns, providing a more objective method for ADHD diagnosis.
- Clinical Application Potential: The newly identified biomarkers will offer clinicians an objective tool to differentiate between hyperactive-impulsive, inattentive, and combined-type ADHD, thereby supporting more precise treatment decisions and medication selection.
- Long-Term Strategic Goal: Firefly's research also advances its broader goal of building a large-scale EEG/ERP 'brain functional model' trained on over 191,000 brain scans, enhancing its competitiveness in the neuroscience field.
See More
Firefly Neuroscience Shares Surge 43% on ADHD Biomarker Discovery
- Significant Stock Surge: Firefly Neuroscience, Inc. (AIFF) shares surged approximately 43% during Friday morning trading, currently priced at $2.50, up from an opening price of $1.90, reaching a high of $2.64, indicating strong market reaction to its recent announcement.
- Discovery of New Biomarkers: The company announced the discovery of new brain wave biomarkers for the differential diagnosis of ADHD, a breakthrough that will assist healthcare professionals in accurately identifying ADHD subtypes, thereby enabling more tailored treatment plans.
- Technological Application Potential: Utilizing the company's AI-powered EEG/ERP technology, health experts can more effectively determine treatment types and dosage decisions for patients, as well as monitor the effectiveness of interventions, enhancing the precision of ADHD treatment.
- Market Performance Analysis: Over the past year, AIFF's stock has fluctuated between $0.62 and $6.00, with the current price increase reflecting investor confidence in the company's growth potential, particularly in innovative applications within the ADHD sector.
See More
Firefly Neuroscience Expands Commercial Footprint 20-Fold
- Commercial Footprint Expansion: Firefly Neuroscience reported a remarkable 20-fold expansion of its commercial footprint, with partnerships reaching 99 and over 10,800 EEG/ERP brain scans completed, indicating strong growth potential in the market.
- Clinical Assessment Surge: Year-over-year, partner sites increased by 1,880% and clinical assessments surged by 3,227%, showcasing the company's rapid development and significant market acceptance in brain scanning technologies.
- Database Growth: Firefly's proprietary database now contains over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository, which lays a solid foundation for future research and commercial applications.
- Stock Performance: Despite a 63.40% decline in share price over the past 12 months, the stock is currently trading 103.6% above its 20-day simple moving average, indicating a strong short-term rebound; however, the RSI suggests overbought conditions, warranting caution for investors.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Firefly Neuroscience's EEG Tech Enhances ADHD Diagnosis
- Technological Innovation: Firefly Neuroscience's EEG/ERP technology can analyze resting and cognitive EEG brain scans to identify patterns that differentiate hyperactive-impulsive, inattentive, and combined forms of ADHD, providing doctors with more accurate diagnostic support.
- Market Reaction: Following the announcement that its AI-powered technology could help identify ADHD subtypes, Firefly's stock soared approximately 50% on Friday, reaching its highest level in nearly five months, reflecting strong investor confidence in the technology's potential.
- Performance Growth: Since acquiring Evoke Neuroscience in May 2025, Firefly has increased EEG/ERP brain scan volumes by 33 times, and on March 4, the stock price surged 126%, showcasing a significant achievement with its commercial footprint expanding over 20-fold.
- Future Outlook: Firefly's acceptance into the NVIDIA Connect program aims to leverage NVIDIA's tools and resources to develop a foundational model of the human brain, with CEO Greg Lipschitz stating that the growing brain scan data and NVIDIA GPU acceleration will lead to further breakthroughs in cognitive brain biomarker discovery.
See More
Firefly Neuroscience Shares Surge 48% on ADHD Biomarker Discovery
- Breakthrough Discovery: Firefly Neuroscience announced a breakthrough in identifying new brain-wave biomarkers that may help distinguish between the three major subtypes of ADHD, leading to a stock price surge of over 48%.
- FDA-Cleared Platform: The findings stem from Firefly's FDA-cleared Evoke EEG/ERP platform, which employs AI to analyze brain signal patterns, providing a more objective method for ADHD diagnosis.
- Clinical Application Potential: The newly identified biomarkers will offer clinicians an objective tool to differentiate between hyperactive-impulsive, inattentive, and combined-type ADHD, thereby supporting more precise treatment decisions and medication selection.
- Long-Term Strategic Goal: Firefly's research also advances its broader goal of building a large-scale EEG/ERP 'brain functional model' trained on over 191,000 brain scans, enhancing its competitiveness in the neuroscience field.
See More
Firefly Neuroscience Shares Surge 43% on ADHD Biomarker Discovery
- Significant Stock Surge: Firefly Neuroscience, Inc. (AIFF) shares surged approximately 43% during Friday morning trading, currently priced at $2.50, up from an opening price of $1.90, reaching a high of $2.64, indicating strong market reaction to its recent announcement.
- Discovery of New Biomarkers: The company announced the discovery of new brain wave biomarkers for the differential diagnosis of ADHD, a breakthrough that will assist healthcare professionals in accurately identifying ADHD subtypes, thereby enabling more tailored treatment plans.
- Technological Application Potential: Utilizing the company's AI-powered EEG/ERP technology, health experts can more effectively determine treatment types and dosage decisions for patients, as well as monitor the effectiveness of interventions, enhancing the precision of ADHD treatment.
- Market Performance Analysis: Over the past year, AIFF's stock has fluctuated between $0.62 and $6.00, with the current price increase reflecting investor confidence in the company's growth potential, particularly in innovative applications within the ADHD sector.
See More
Firefly Neuroscience Expands Commercial Footprint 20-Fold
- Commercial Footprint Expansion: Firefly Neuroscience reported a remarkable 20-fold expansion of its commercial footprint, with partnerships reaching 99 and over 10,800 EEG/ERP brain scans completed, indicating strong growth potential in the market.
- Clinical Assessment Surge: Year-over-year, partner sites increased by 1,880% and clinical assessments surged by 3,227%, showcasing the company's rapid development and significant market acceptance in brain scanning technologies.
- Database Growth: Firefly's proprietary database now contains over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository, which lays a solid foundation for future research and commercial applications.
- Stock Performance: Despite a 63.40% decline in share price over the past 12 months, the stock is currently trading 103.6% above its 20-day simple moving average, indicating a strong short-term rebound; however, the RSI suggests overbought conditions, warranting caution for investors.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
